CR9953A - Diarilurea para el tratamiento de hipertension pulmonar - Google Patents

Diarilurea para el tratamiento de hipertension pulmonar

Info

Publication number
CR9953A
CR9953A CR9953A CR9953A CR9953A CR 9953 A CR9953 A CR 9953A CR 9953 A CR9953 A CR 9953A CR 9953 A CR9953 A CR 9953A CR 9953 A CR9953 A CR 9953A
Authority
CR
Costa Rica
Prior art keywords
treatment
pulmonary hypertension
diarilure
methylamide
fluorophenoxy
Prior art date
Application number
CR9953A
Other languages
English (en)
Inventor
Sandner Peter
Tinel Hanna
Hutter Joachim
Riedl Bernd
Klein Martina
Original Assignee
Bayer Shering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Shering Pharma Ag filed Critical Bayer Shering Pharma Ag
Publication of CR9953A publication Critical patent/CR9953A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invencion se refiere a composiciones farmaceuticas para el tratamiento, prevencion o control de hipertension pulmonar que comprenden metilamida del acido 4{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridina-2-carboxilico, opcionalmente combinada con al menos un agente terapeutico adicional.
CR9953A 2005-11-10 2008-05-06 Diarilurea para el tratamiento de hipertension pulmonar CR9953A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05024509 2005-11-10
EP05027450 2005-12-15
EP06012234 2006-06-14

Publications (1)

Publication Number Publication Date
CR9953A true CR9953A (es) 2008-10-08

Family

ID=37622057

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9953A CR9953A (es) 2005-11-10 2008-05-06 Diarilurea para el tratamiento de hipertension pulmonar

Country Status (18)

Country Link
US (1) US20100035888A1 (es)
EP (1) EP1948170A1 (es)
JP (1) JP5084736B2 (es)
KR (1) KR20080067000A (es)
AR (1) AR057849A1 (es)
AU (1) AU2006312714A1 (es)
BR (1) BRPI0618522A2 (es)
CA (1) CA2628849A1 (es)
CR (1) CR9953A (es)
EC (1) ECSP088430A (es)
GT (1) GT200800058A (es)
IL (1) IL191178A0 (es)
NO (1) NO20082498L (es)
PE (1) PE20070806A1 (es)
SV (1) SV2009002900A (es)
TW (1) TW200733961A (es)
UY (1) UY29903A1 (es)
WO (1) WO2007054216A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) * 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2002534468A (ja) * 1999-01-13 2002-10-15 バイエル コーポレイション ｐ３８キナーゼ阻害剤としてのω−カルボキシアリール置換ジフェニル尿素
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
WO2003068228A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
NZ562414A (en) * 2003-02-21 2009-02-28 Resmed Ltd Headgear assembly for nasal pillow mask
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
PT1636585E (pt) * 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
US8637553B2 (en) 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
KR20090018224A (ko) * 2004-09-29 2009-02-19 바이엘 헬스케어 아게 열역학적으로 안정한 형태의 ｂａｙ 43-9006 토실레이트
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
JP5885012B2 (ja) * 2007-01-19 2016-03-15 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ Ｋｉｔ阻害剤に対して獲得した抵抗性を有する癌の処置
US20110178137A1 (en) * 2008-06-25 2011-07-21 Bayer Schering Pharma Aktiengesellschaft Diaryl urea for treating heart failure
CA2796744A1 (en) * 2010-04-17 2011-10-20 Bayer Healthcare Llc Synthetic metabolites of fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
SG189038A1 (en) 2010-10-01 2013-05-31 Bayer Ip Gmbh Substituted n-(2-arylamino)aryl sulfonamide-containing combinations
GB2503181A (en) * 2011-03-14 2013-12-18 Cellworks Res India Private Ltd Compositions, process of preparation of said compositions and method of treating inflammatory diseases
EP3082428A4 (en) 2013-12-09 2017-08-02 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068228A1 (en) * 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
ES2303585T3 (es) * 2002-04-10 2008-08-16 Virginia Commonwealth University Combinacion de glivec(sti571) con un inhibidor de quinasa dependiente de ciclina, especialmente flavopiridol en el tratamiento de cancer.
PT1636585E (pt) * 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
US8637553B2 (en) * 2003-07-23 2014-01-28 Bayer Healthcare Llc Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
WO2006091542A2 (en) * 2005-02-22 2006-08-31 Cedars-Sinai Medical Center Use of sildenafil, vardenafil and other 5-phosphodiesterase inhibitors to enhance permeability of the abnormal blood-brain barrier

Also Published As

Publication number Publication date
ECSP088430A (es) 2008-07-30
EP1948170A1 (en) 2008-07-30
KR20080067000A (ko) 2008-07-17
SV2009002900A (es) 2009-04-28
WO2007054216A1 (en) 2007-05-18
UY29903A1 (es) 2007-06-29
GT200800058A (es) 2010-02-23
US20100035888A1 (en) 2010-02-11
BRPI0618522A2 (pt) 2011-09-06
AU2006312714A1 (en) 2007-05-18
JP5084736B2 (ja) 2012-11-28
CA2628849A1 (en) 2007-05-18
NO20082498L (no) 2008-08-07
TW200733961A (en) 2007-09-16
PE20070806A1 (es) 2007-09-29
IL191178A0 (en) 2009-08-03
JP2009514910A (ja) 2009-04-09
AR057849A1 (es) 2007-12-19

Similar Documents

Publication Publication Date Title
CR9953A (es) Diarilurea para el tratamiento de hipertension pulmonar
HN2005000255A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
CU20080082A7 (es) Diarilureas para el tratamiento de hipertensión pulmonar
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
BR112015023349A2 (pt) composto, composição farmacêutica, e, método de tratamento de uma doença, condição de saúde ou distúrbio
CR11292A (es) Compuestos y composiciones como moduladores de la actividad de gpr119
UY29983A1 (es) Derivados de 4-amino-pirrolotriazina sustituida utiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogenesis
NO20045429L (no) Kombinasjon av organiske forbindelser
PA8780201A1 (es) Derivados de pirasol sustituidos con heteroaril utiles para tratar trastornos hiperproliferativos y enfermedades asociadas con angiogénesis
ECSP088852A (es) Azolopirimidinas como inhibidores de la actividad canabinoidea 1
DOP2006000170A (es) Nuevos derivados de espirocromanona
NO20083836L (no) N-hydroksyakrylamidforbindelser
DOP2007000053A (es) Compuestos de tetrahidropiridotienopirimidina y métodos para su empleo
DE602005016803D1 (de) Zusammensetzungen mit strontium und vitamin d und ihre verwendungen
BRPI0807528A2 (pt) Composições lubrificantes pessoais complementares
BRPI0607003A2 (pt) forma de dosagem com liberação sustentada e método para liberação sustentada de um composto de pirazina substituìda
DOP2007000073A (es) Compuestos para tratar la hipertensión pulmonar
ATE437988T1 (de) Neues imprägnierverfahren einer textiloberfläche
MX2010001243A (es) Composicion anti-inflamatoria.
NO20076405L (no) Anvendelse av 24-nor-UDCA
EA200600590A1 (ru) Фармацевтические композиции модафинила с модифицированным высвобождением
DOP2006000244A (es) Diarilurea para el tratamiento de hipertensión pulmonar
BRPI0817563A2 (pt) Composições farmacêuticas que compreendem a combinação de um agente antiinflamatório não esteróide e um agente inibidor da xantino oxidase úteis para o controle e tratamento da gota, artrite gotosas e enfermidades relacionadas
BR112012024346A2 (pt) agente terapêutico ou agente profilático para a doença de alzheimer
CU20080078A7 (es) Diarilurea para el tratamiento de hipertensión pulmonar

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)